1. Home
  2. ADVM vs BMHL Comparison

ADVM vs BMHL Comparison

Compare ADVM & BMHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • BMHL
  • Stock Information
  • Founded
  • ADVM 2006
  • BMHL 2016
  • Country
  • ADVM United States
  • BMHL Hong Kong
  • Employees
  • ADVM N/A
  • BMHL N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • BMHL
  • Sector
  • ADVM Health Care
  • BMHL
  • Exchange
  • ADVM Nasdaq
  • BMHL Nasdaq
  • Market Cap
  • ADVM 94.6M
  • BMHL 78.3M
  • IPO Year
  • ADVM 2014
  • BMHL 2025
  • Fundamental
  • Price
  • ADVM $4.31
  • BMHL $3.06
  • Analyst Decision
  • ADVM Buy
  • BMHL
  • Analyst Count
  • ADVM 5
  • BMHL 0
  • Target Price
  • ADVM $16.60
  • BMHL N/A
  • AVG Volume (30 Days)
  • ADVM 1.0M
  • BMHL 5.2K
  • Earning Date
  • ADVM 11-07-2025
  • BMHL 11-21-2025
  • Dividend Yield
  • ADVM N/A
  • BMHL N/A
  • EPS Growth
  • ADVM N/A
  • BMHL 9.50
  • EPS
  • ADVM N/A
  • BMHL 0.05
  • Revenue
  • ADVM $1,000,000.00
  • BMHL $6,873,097.00
  • Revenue This Year
  • ADVM $1,191.10
  • BMHL N/A
  • Revenue Next Year
  • ADVM N/A
  • BMHL N/A
  • P/E Ratio
  • ADVM N/A
  • BMHL $57.77
  • Revenue Growth
  • ADVM N/A
  • BMHL 66.02
  • 52 Week Low
  • ADVM $1.78
  • BMHL $2.72
  • 52 Week High
  • ADVM $8.18
  • BMHL $4.49
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 50.55
  • BMHL N/A
  • Support Level
  • ADVM $4.18
  • BMHL N/A
  • Resistance Level
  • ADVM $4.37
  • BMHL N/A
  • Average True Range (ATR)
  • ADVM 0.20
  • BMHL 0.00
  • MACD
  • ADVM -0.03
  • BMHL 0.00
  • Stochastic Oscillator
  • ADVM 51.58
  • BMHL 0.00

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About BMHL Bluemount Holdings Limited Class B Ordinary Shares

Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.

Share on Social Networks: